Prof. George Lau served as assistant dean of the Li Ka Shing Faculty of Medicine of the University of Hong Kong, clinical professor of gastroenterology and hepatology, and 19th President of The Asian Pacific Association f...
Rivoceranib plus camrelizumab was approved by China’s National Medical Products Administration as a first-line treatment for patients with liver cancer in February 2023.1 References Elevar Therapeutics announces FDA acceptance for filing of new drug application for rivoceranib in combination with ca...
Based on these findings, Exelixis, Inc. shared that they do not intend to submit a supplemental new drug application to the FDA for the combination in this indication. However, they do plan to share full results at a future medical conference. “Exelixis has a longstanding commitment to pa...
Prof. George Lau served as assistant dean of the Li Ka Shing Faculty of Medicine of the University of Hong Kong, clinical professor of gastroenterology and hepatology, and 19th President of The Asian Pacific Association for the Study of the Liver (APASL). Prof. Lau has received many awards a...
In addition to the interpretation of AI-based-models-provided results, another relevant issue influencing the application of these tools in routine clinical practice is warranting the safety of the HCC patients and the relative data, constituting simultaneously a medical and an ethical question [108]...
Application Process Families and individuals interested in the Health Care Center are encouraged to schedule a tour of our home, complete an application for residency, make a $500 deposit and secure a place on the waiting list. The $500 deposit is applied to the first monthly statement or is...
Prof. George Lau served as assistant dean of the Li Ka Shing Faculty of Medicine of the University of Hong Kong, clinical professor of gastroenterology and hepatology, and 19th President of The Asian Pacific Association ...
Prof. George Lau served as assistant dean of the Li Ka Shing Faculty of Medicine of the University of Hong Kong, clinical professor of gastroenterology and hepatology, and 19th President of The Asian Pacific Association for the Study of the Liver (APASL). Prof. Lau has received many awards ...
Moreover, the accelerated approval of the combination of nivolumab and ipilimumab for the treatment of patients with HCC who have received prior therapy with sorafenib would be maintained pending confirmatory data, irrespective of the decision of the biologics license application for nivolumab monotherapy...